Group 1: Stock Performance - Yibin Paper (600793.SH) has experienced a significant short-term stock price increase and a substantial rise in trading volume [1] - Sanofi Health (688336.SH) has seen a cumulative stock price increase of over 100% since May 19, 2025, indicating potential irrational speculation and a possible correction [1] - Laisun Tongling (603900.SH) has shown a notable short-term increase in stock price and turnover rate, exceeding most companies in the industry [1] Group 2: Project Investments - Youyan Powder Materials (688456.SH) plans to establish a subsidiary to invest in an additive manufacturing metal powder materials industrial base [1] - Suqian Agricultural Development (601952.SH) intends to initiate a project for the construction of a 14,000-ton grain storage facility [1] Group 3: Contract Awards - Zhongnan Media (601098.SH) has signed a procurement contract through its wholly-owned subsidiary [1] Group 4: Operating Data - China Power Construction (601669.SH) reported a total new contract amount of 386.49 billion yuan from January to April, a year-on-year decrease of 4.9% [1] - China Chemical (601117.SH) recorded a total contract amount of 123.017 billion yuan from January to April [1] Group 5: Equity Acquisitions - Health元 (600380.SH) announced that its controlling subsidiary, Lizhu Group, plans to acquire equity in Vietnam's IMP company [1] Group 6: Share Buybacks - Geling Deep Vision (688207.SH) has completed a buyback of 1.29% of its shares [1] Group 7: Shareholding Changes - Yiwan Yichuang (300792.SZ) shareholders Zhang Fan and director Lu Hualiang plan to reduce their holdings by up to 3.02% [1] - Daqian Ecology (603955.SH) has announced that Xinhua Publishing Group intends to reduce its holdings by up to 3% [1] - Hongli Zhihui (300219.SZ) controlling shareholder plans to increase holdings by 25 million to 50 million yuan [1] - Sanfeng Environment (601827.SH) controlling shareholder intends to increase holdings by 150 million to 300 million yuan [1] - Chengdu Xian Dao (688222.SH) plans to increase holdings by 25 million to 50 million yuan [1] Group 8: Strategic Partnerships - Tiantie Technology (300587.SZ) has signed a strategic cooperation framework agreement with Xinjie Energy [2]

健康元药业集团 九届董事会十次会议 证券代码：600380 证券简称：健康元 公告编号：临 2025-043 健康元药业集团股份有限公司 九届董事会十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届董事会十次会议于 2025 年 5 月 16 日（星期五）以电子邮件并电话确认的形式发出会议通知，并于 2025 年 5 月 22 日（星期四）以通讯表决形式召开。会议应参加董事九人，实际参加董事九人， 公司三名监事会成员、总裁清楚本次会议议案并无任何异议，符合《公司法》及《公 司章程》的规定。会议审议并通过如下议案： 一、审议并通过《关于控股子公司丽珠集团拟收购越南 IMP 公司股权的议案》 同意本公司控股子公司丽珠医药集团股份有限公司全资附属公司 LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）与 SK Investment Vina III Pte. Ltd.（以 下简称"SK"）、Sunrise Kim Investment ...

Group 1 - The company intends to acquire 64.81% of Imexpharm Corporation (IMP) in Vietnam for approximately 5.73 trillion VND, equivalent to about 1.587 billion RMB, which represents 10.92% of the company's latest audited net assets [2][3] - The acquisition will be executed by LIAN SGP, a wholly-owned subsidiary of the company's controlling subsidiary, Lijun Group, and will not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [2][3] - The transaction has been approved by the company's board of directors and does not require shareholder approval [2][3] Group 2 - The target company, IMP, is a leading pharmaceutical enterprise in Vietnam, primarily engaged in the research, production, and sale of pharmaceuticals, including antibiotics and cardiovascular drugs, which align well with the existing product portfolio of Lijun Group [5][6] - The acquisition is expected to strengthen the company's international market presence and support its long-term strategy for sustainable development in the pharmaceutical sector [8] Group 3 - The transaction is subject to certain conditions, including regulatory approvals in Vietnam, and the company will comply with all necessary legal and regulatory requirements [3][10] - The acquisition will not involve personnel placement, land leasing, or debt restructuring, and upon completion, IMP will become a controlled subsidiary within the company's consolidated financial statements [8][9]

健康元药业集团 丽珠集团拟收购越南 IMP 公司股权的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-044 健康元药业集团股份有限公司 关于控股子公司丽珠集团拟收购越南 IMP 公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●健康元药业集团股份有限公司（以下简称：本公司）控股子公司丽珠医药集 团股份有限公司（以下简称"丽珠集团"）之全资附属公司LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）拟以5,730,815,426,000越南盾（折合约为人民币 15.87亿元）收购越南上市公司Imexpharm Corporation 64.81%股份。 本次交易完成后，标的公司将成为本公司合并报表范围内的附属公司。 ●本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的上市公司重大资产重组。 ●本次交易已经公司九届董事会十次会议审议通过，根据《上海证券交易所股 票上市规则》等相关规定，本议案拟定事项在董事会的审议权限范围内 ...

健康元药业集团 九届董事会十次会议 证券代码：600380 证券简称：健康元 公告编号：临 2025-043 健康元药业集团股份有限公司 九届董事会十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届董事会十次会议于 2025 年 5 月 16 日（星期五）以电子邮件并电话确认的形式发出会议通知，并于 2025 年 5 月 22 日（星期四）以通讯表决形式召开。会议应参加董事九人，实际参加董事九人， 公司三名监事会成员、总裁清楚本次会议议案并无任何异议，符合《公司法》及《公 司章程》的规定。会议审议并通过如下议案： 同意本公司控股子公司丽珠医药集团股份有限公司全资附属公司 LIAN SGP HOLDING PTE.LTD.（以下简称"LIAN SGP"）与 SK Investment Vina III Pte. Ltd.（以 下简称"SK"）、Sunrise Kim Investment Joint Stock Company（以下简称"Sunrise"） 及 K ...

Summary of Key Points Core Viewpoint - The company held a performance and cash dividend briefing for the fiscal year 2024 and the first quarter of 2025, emphasizing its optimistic outlook for the pharmaceutical industry driven by multiple favorable factors [1][2]. Company Performance and Strategy - The company is focusing on innovative drugs as its core development direction, particularly in the respiratory disease treatment area, with over ten innovative drug projects in the pipeline [3][5]. - The company has successfully reserved over twenty innovative drugs covering various important therapeutic areas, with several entering critical clinical phases [3][5]. - The company aims to enhance its operational efficiency and resource utilization to achieve sustainable growth [6]. Industry Outlook - The pharmaceutical industry is expected to experience medium to high-speed growth, with significant improvements in innovation capabilities and modernization of the industrial chain by 2025 [5]. - The industry reported a total revenue of 25,298.5 billion yuan in 2024, with a slight decrease in total profit by 1.1% year-on-year due to temporary adjustments [5]. Financial Performance - The company reported a steady performance in the first quarter of 2025, despite facing some pressure from industry policy adjustments [9]. - The company's R&D expenses for 2024 are projected to be around 400 million yuan, reflecting a year-on-year increase of approximately 30% [8]. Market Development - The company is actively working on market expansion for its newly approved products, such as the Tobramycin inhalation solution and the Salmeterol/Fluticasone inhalation powder, aiming for significant growth contributions in the coming years [6][9].

健康元药业集团 关于 2024 年度暨 2025 年第一季度业绩暨现金分红说明会召开情况的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-042 健康元药业集团股份有限公司关于 2024 年度暨 2025 年第一季度业绩暨现金分红说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：公司）于 2025 年 05 月 12 日（星期一）下 午 15:00-17:00 在上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/），以 视频与网络文字互动方式召开了 2024 年度暨 2025 年第一季度业绩暨现金分红说明会，针 对公司 2024 年度及 2025 年第一季度的经营成果及财务指标等具体情况与投资者进行互动 交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行现场回复，现就有关 情况公告如下： 一、本次说明会召开情况 2025 年 05 月 12 日（星期一）下午 15:00-17:00，公司在上海证券 ...

Core Viewpoint - Health元药业's subsidiary, Lijuzhu Microball Technology Co., Ltd., has received approval for the injectable Aripiprazole microspheres, which is expected to enhance medication adherence and reduce relapse rates in adult schizophrenia patients [1][2]. Group 1: Drug Registration Details - The drug is named Aripiprazole Microspheres for Injection, with a dosage of 350mg [1]. - The registration certificate was issued by the National Medical Products Administration, confirming compliance with drug registration requirements [1]. - The drug is classified as a chemical drug of category 2.2 and is produced by Zhuhai Lijuzhu Microball Technology Co., Ltd. [1]. Group 2: Drug Development and Market Context - The injectable Aripiprazole microspheres were submitted for market approval in September 2023, with the acceptance number CXHS2300080 [2]. - This long-acting formulation is designed for monthly administration, which can improve patient compliance and reduce both economic and social burdens [2]. - As of the announcement date, Lijuzhu Microball is the only company with production approval for Aripiprazole microspheres, with no other similar products available globally [2]. Group 3: Market Potential - The estimated terminal sales value of antipsychotic drugs in China for 2024 is approximately RMB 6.048 billion, with long-acting formulations accounting for around RMB 1.418 billion [2].

北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 健康元药业集团股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会（以下简称"本次会议"）于 2025 年 5 月 9 日（星期五）召开。北京德 恒（深圳）律师事务所（以下简称"德恒"或"本所"）受公司委托，指派皇甫 天致律师、黄俐娜律师（以下简称"本所律师"）出席了本次会议。根据《中华 人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》 （以下简称"《公司法》"）、中国证券监督管理委员会《上市公司股东会规则》 （以下简称"《股东会规则》"）等法律、行政法规、部门规章、规范性文件和《健 康元药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，本所 律师就本次会议的召集、召开程序、现场出席会议人员资格、表决程序、表决结 果等相关事项进行见 ...

健康元药业集团 2025 年第一次临时股东大会决议公告 （2）出席会议的股东所持有表决权的股份总数（股） 941,189,317 （3）出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） 51.4464 本次会议由公司董事会召集，经半数以上董事推举，董事林楠棋先生主持本次 证券代码：600380 证券简称：健康元 公告编号：2025-041 健康元药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 团大厦二号会议室 （1）出席会议的股东和代理人人数 530 会议。本次会议以现场投票及网络投票相结合的方式进行表决，会议的召集、召开 和表决方式符合《公司法》、《上市公司股东大会规则》及《公司章程》的有关规 定，本次会议决议有效。 （1）公司在任董事9人，出席9人，其中董事兼总裁林楠棋先生、董事兼副总 裁、财务负责人邱庆丰先生、董事兼副总裁幸志伟先生、独立董事印晓星先生现场 出席；董事长朱保国先生、副董事长刘广霞女士、独立董事覃业 ...